Review Article

Association of Adult Height with Cardiovascular Mortality: A Systematic Review and Meta-Analysis of Cohort Studies

Obaidullah Fahim,1,2 Sina Naghshi,3,4 Zainab Khademi,1,5 and Ahmad Esmailzadeh1,6,7

1Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran
2Department of Nutrition, Faculty of Public Health, Kabul University of Medical Science, Kabul, Afghanistan
3Students’ Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran
4Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran
5Department of Public Health, Sirjan School of Medical Sciences, Sirjan, Iran
6Obesity and Eating Habits Research Center, Endocrinology and Metabolism Molecular—Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
7Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran

Correspondence should be addressed to Ahmad Esmailzadeh; a.esmailzadeh@gmail.com

Received 20 August 2022; Accepted 10 September 2022; Published 26 October 2022

Academic Editor: Pietro Scicchitano

Copyright © 2022 Obaidullah Fahim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Epidemiological studies on the association between adult height and cardiovascular disease (CVD) mortality have provided conflicting findings. We examined the association between adult height and the risk of CVD mortality. Methods. We searched PubMed, Scopus, ISI Web of Knowledge, and Google Scholar for relevant studies published up to September 2021. Prospective cohort studies that reported the risk estimates for death from CVD, coronary heart disease (CHD), and stroke were included. The random-effects model was used to calculate summary relative risks (RRs) and 95% confidence intervals (CIs) for the highest vs. lowest categories of adult height. Results. In total, 20 prospective cohort publications were included in this systematic review and 17 in the meta-analysis. During 5 to 41 years of follow-up, the total number of deaths from CVD was 95,197 (51,608 from CHD and 20,319 from a stroke) among 2,676,070 participants. The summary RR comparing the highest and lowest categories of height was 0.80 (95% CI: 0.74–0.87, 𝑃2 = 59.4%, 𝑛 = 15 studies) for CVD mortality, 0.82 (95% CI: 0.74–0.90, 𝑃2 = 70.6%, 𝑛 = 12) for CHD mortality, 0.73 (95% CI: 0.67–0.80, 𝑃2 = 0%, 𝑛 = 10) for stroke mortality, 0.70 (95% CI: 0.61–0.81, 𝑃2 = 0%, 𝑛 = 4) for hemorrhagic stroke mortality, and 0.88 (95% CI: 0.72–1.08, 𝑃2 = 0%, 𝑛 = 4) for ischemic stroke mortality. Conclusion. The present comprehensive meta-analysis provides evidence for an inverse association between adult height and the risk of CVD, CHD, and stroke mortality.

1. Introduction

Cardiovascular disease (CVD) is now a public health crisis, affecting millions of people in both developed and developing countries. It is one of the most common causes of death [1]. Although obesity is a well-known risk factor for CVD [2], increasing evidence suggests that other body size indicators are involved in CVD development and its mortality. Adult height, which is determined by both genetic and environmental factors, is considered a surrogate marker for in utero and childhood conditions [3]. Although adult height is not a modifiable risk factor, it can provide insights into patterns of early determinants of major diseases of later life. Therefore, studying height would be informative to identify the effects of early diet on CVD risk in later life.
Taller adult height was associated with a reduced risk of all-cause mortality and an increased risk of cancer mortality. However, epidemiological studies on the association between adult height and CVD mortality have provided conflicting findings. Higher height was associated with an increased risk of CVD mortality in a study among females [4], while others reported an inverse association [5–7] or no clear significant association [8, 9]. A recent individual participant meta-analysis showed that adult height was inversely associated with the risk of death from circulatory diseases such as coronary disease, stroke, and heart failure [10]. However, several large relevant studies have been published since the release of that meta-analysis and have reported conflicting results [4, 5, 11–12]. To combine these findings and reach a definite conclusion, we conducted the current comprehensive systematic review and meta-analysis to summarize the available data on the association between adult height and CVD mortality.

2. Methods

We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines for reporting the present meta-analysis.

2.1. Search Strategy. We carried out a systematic literature search using online databases, including PubMed, Scopus, ISI Web of Knowledge, and Google Scholar, to identify relevant papers published up to September 2021. No language or time limitations were performed. In the search strategy, a combination of MeSH (medical subject heading terms) and non-MeSH terms was used (Supplementary Table 1). References from all relevant articles were checked to not miss any study.

2.2. Eligibility Criteria. Two of the authors (OF and ZK) screened the titles and abstracts of all studies found in the systematic search to identify studies that met our criteria for inclusion in the meta-analysis. Studies were selected if they (1) had a prospective observational design; (2) were conducted on the adult population; and (3) reported relative risks, including risk ratios (RRs), hazard ratios (HRs), and odds ratios (ORs) with 95% confidence intervals (CIs) to determine the association of height with the risk of CVD, coronary heart disease (CHD), and stroke mortality. If several publications were reported from a single cohort, the most comprehensive one was included.

2.3. Exclusion Criteria. We excluded letters, comments, reviews, meta-analyses, and ecological studies. We also excluded studies that were conducted on children or adolescents and publications that reported RRs for cardiovascular and respiratory disorder mortality combined.

2.4. Data Extraction. After the study selection process, two reviewers (OF and SN) independently extracted data from the original cohort studies. The following items were extracted from each eligible study: the first author’s name, publication year, cohort name, country, age range or mean age of study participants, gender, sample size, number of CVD deaths, follow-up duration, height assessment methods, comparison categories, adjusted RR with 95% CI for CVD mortality, and covariates adjusted in the statistical analysis. The greatest degree of adjustment from each study was considered and used for the meta-analysis. Any disagreements between the reviewers were discussed and resolved by the third reviewer (AE).

2.5. Quality Assessment of Studies. The Newcastle-Ottawa scale was used to assess the quality of each study. This tool consists of several parts, including the selection of participants (4 scores), comparability (2 scores), and ascertainment of exposure or outcome (3 scores). The total score of NOS ranges between 0 and 9. Studies achieving nine points were considered to provide the highest quality.

2.6. Patient and Public Involvement. No patients were involved in the design, conduct, reporting, or dissemination plans of our research.

2.7. Statistical Methods. ORs, RRs, and HRs (and 95% CIs) for comparison of the highest and lowest categories of adult height were used to calculate log RR, OR, and HR ± SE. The analyses were performed with the use of a random-effects model to account for between-study heterogeneity. We assessed heterogeneity between studies using Cochran’s $\chi^2$ test and quantified the inconsistencies using the I² statistic. For the I² statistic, we considered the I² values of 25%, 50%, and 75% as low, moderate, and high between-study heterogeneity, respectively [13]. We also used the method of Hamling and colleagues [14] to convert risk estimates when the lowest category was not the reference category.

Two studies [15, 16] reported only risk estimates but not corresponding 95% confidence intervals. We calculated 95% confidence intervals by using $P$ values and effect estimates [17]. When studies reported risk estimates for CHD and stroke but not for CVD mortality, we pooled risk estimates for CHD and stroke using a fixed-effects model. Then, the pooled risk estimate was included in the meta-analysis of CVD mortality. In case of finding a significant between-study heterogeneity, we performed stratified analyses to explore possible sources of heterogeneity. Between-subgroup heterogeneity was examined through a fixed-effects model. If ≥10 studies were available, we examined the possibility of publication bias by inspecting funnel plots and conducting Egger’s and Begg’s tests [18]. In case of a significant publication bias, the trim-and-fill method was used to detect the effect of missing studies on the overall effect of meta-analysis. The influence of each individual study on the summary RR was examined by excluding the study in turn. Statistical analyses were conducted using STATA version 14.0. $P < 0.05$ was considered statistically significant for all tests, including Cochran’s $Q$ test.
3. Results

3.1. Literature Search. The flow diagram of study selection is shown in Figure 1. Our initial search identified 2127 publications. After excluding duplicates and papers that did not meet the inclusion criteria, 45 remaining papers seemed to be relevant for this meta-analysis. After examination of full texts, an additional 25 papers were excluded: fifteen that reported risk estimates for fatal and nonfatal CVD events combined, eight that were conducted on the same populations with the same outcomes, and two with a case-control design. Finally, 20 publications were included in the systematic review [4–12, 15, 16, 19–27], and 17 were included in the meta-analysis [4–8, 10–12, 15, 20–27].

3.2. Characteristics of the Included Studies. Characteristics of the 20 included articles are shown in Supplemental Table 2. All the included articles were published between 1994 and 2021. The number of participants in these studies varied from 1441 to 1,085,949, with an age range between 14 and 99 years. The duration of follow-up time ranged from 5 to 41 years, and the total number of CVD deaths was 95,197 (51,608 from CHD and 20,319 from stroke) among 2,676,070 participants.

Among the 20 included articles, six included only men [5, 7, 8, 20, 21, 24], one included only women [6], and twelve had reported risk estimates for men and women separately [4, 10–12, 15, 16, 19, 22, 23, 25–27]. In total, three papers described studies conducted in the United States [7, 15, 23], sixteen in non-US countries [4–6, 8, 10–12, 16, 19–22, 24–27], and one publication described studies conducted in US and non-US countries [9]. In three publications, height was obtained from a self-reported questionnaire, in sixteen articles, height was measured, and one publication described studies in which both approaches were applied. Most included publications had adjusted for some potential confounders, including body mass index (BMI) (n = 16), smoking (n = 18), alcohol consumption (n = 11), and physical activity (n = 8). Based on the NOS score [28], all publications, which had a total score above the median (≥7), were defined as high quality (Supplemental Table 3).

3.3. Findings from the Meta-Analysis

3.3.1. Adult Height and Total CVD Mortality. Fifteen cohort studies (14 publications) [4–8, 10–12, 15, 20–21, 23, 24, 27] investigated the association between adult height and CVD mortality (stroke and CHD combined). These studies included a total of 1510355 participants with 28955 CVD deaths. Combining RRs from these studies, comparing the highest and lowest categories of adult height, a significant inverse association was seen between adult height and CHD mortality (pooled RR: 0.82; 95% CI: 0.74–0.90), with a significant between-study heterogeneity (I² = 70.6%; P_heterogeneity<0.001) (Figure 3) There was no evidence of small study bias using Egger’s test or Begg’s test.

3.3.2. Adult Height and CHD Mortality. In total, 12 studies (11 publications) were included in this meta-analysis [4–6, 8, 12, 20, 21, 24–27]. These studies included a total of 1439521 participants and 16,484 CHD deaths. Considering the highest versus lowest categories of adult height, a significant inverse association was seen between adult height and CHD mortality (pooled RR: 0.82; 95% CI: 0.74–0.90), with a significant between-study heterogeneity (I² = 70.6%; P_heterogeneity<0.001) (Figure 3) There was no evidence of small study bias using Egger’s test or Begg’s test.

3.3.3. Adult Height and Stroke Mortality. Ten cohort studies (nine publications) [4–6, 8, 12, 21, 22, 24, 27] were included in the analysis of adult height and stroke mortality. These studies included a total of 1435375 participants; of them, 7322 died due to stroke. Combining data from these studies indicated a significant inverse association between adult height and risk of stroke mortality (pooled RR: 0.73, 95% CI: 0.67–0.80) (Figure 4). There was no evidence of heterogeneity among studies (I² = 0%; P_heterogeneity = 0.80). We found no substantial publication bias by using Egger’s test and Begg’s test.

3.3.4. Adult Height and Ischemic Stroke Mortality. Four studies [4–6, 12] investigated the association between height and ischemic stroke mortality, with a total of 1248688 participants and 1280 deaths. The summary RR for ischemic stroke mortality, comparing the highest and lowest categories of adult height, was 0.88 (95% CI: 0.72–1.08), indicating no clear significant association between height and ischemic stroke mortality (Figure 5). There was no evidence of heterogeneity between the studies (I² = 0%; P_heterogeneity = 0.50). Publication bias tests were not performed (<10 studies).

3.3.5. Adult Height and Hemorrhagic Stroke Mortality. Four studies [4–6, 12] examined the association between adult height and hemorrhagic stroke mortality. These studies included a total of 1248688 participants and 2646 deaths. Combining data from these studies indicated a significant inverse association between height and hemorrhagic stroke mortality (pooled RR: 0.70, 95% CI: 0.61–0.81) (Figure 6). No heterogeneity of effect estimates on relative risks was observed (I² = 0.0%; P_heterogeneity = 0.61). Publication bias tests were not performed (<10 studies).

3.4. Subgroup and Sensitivity Analyses. Supplemental Table 4 shows findings from the different subgroup analyses. In terms of the heterogeneity observed for the association between adult height and CVD mortality, subgroup analyses showed that location of study conduction, exposure assessment method, and adjustment for alcohol consumption might be involved. Additionally, a significant inverse association was observed between adult height and CVD mortality in most subgroup analyses. In terms of CHD mortality, method of
NOTE: Weights are from random effects analysis

Overall (I-squared = 59.4%, p<0.001)

Wang et al. 2011 (Male)
Cook et al. 1994 (Male)
Zhao et al. 2019 (Female)
Rohrmann et al. 2017 (Male)
Wannamethee et al. 1998
Rohrmann et al. 2017 (Female)
Sawada et al. 2017 (Male)
Ihira et al. 2018 (Male)
Cook et al. 1994 (Female)
Song et al. 2008
Ihira et al. 2018 (Female)
Forsean et al. 2000
Goldbourt and Tanne. 2001
Zhao et al. 2019 (Male)
McCarron et al. 2002
Sawada et al. 2017 (Female)
Kannam et al. 1994 (Male)
Kannam et al. 1994 (Female)
Cook et al. 1994 (Female)
Cook et al. 1994 (Male)
Wannamethee et al. 1998
Forsean et al. 2000
Goldbourt and Tanne. 2001
McCareon et al. 2002
Song et al. 2003
Song et al. 2008
Wang et al. 2011 (Female)
Wang et al. 2011 (Male)
Rohrmann et al. 2017 (Male)
Rohrmann et al. 2017 (Female)
Sawada et al. 2017 (Male)
Sawada et al. 2017 (Female)
Ihira et al. 2018 (Male)
Ihira et al. 2018 (Female)
Zhao et al. 2019 (Female)
Zhao et al. 2019 (Male)

| Study ID | RR (95% CI) | (%) Weight |
|----------|-------------|------------|
| Hebert et al. 1993 | 0.87 (0.44, 1.70) | 1.24 |
| Kannam et al. 1994 (Male) | 1.05 (0.82, 1.35) | 5.02 |
| Kannam et al. 1994 (Female) | 0.74 (0.57, 0.98) | 4.62 |
| Cook et al. 1994 (Female) | 0.61 (0.37, 0.99) | 2.10 |
| Cook et al. 1994 (Male) | 0.82 (0.48, 1.39) | 1.85 |
| Wannamethee et al. 1998 | 0.78 (0.59, 1.05) | 4.32 |
| Forsean et al. 2000 | 0.75 (0.59, 0.95) | 5.24 |
| Goldbourt and Tanne. 2001 | 0.88 (0.76, 1.03) | 7.20 |
| McCareon et al. 2002 | 0.69 (0.48, 0.99) | 3.27 |
| Song et al. 2003 | 0.82 (0.71, 0.95) | 7.35 |
| Song et al. 2008 | 0.71 (0.58, 0.86) | 6.13 |
| Wang et al. 2011 (Female) | 0.74 (0.58, 0.94) | 5.17 |
| Wang et al. 2011 (Male) | 0.84 (0.62, 1.14) | 4.06 |
| Rohrmann et al. 2017 (Male) | 0.85 (0.63, 1.14) | 4.18 |
| Rohrmann et al. 2017 (Female) | 1.35 (1.02, 1.79) | 4.44 |
| Sawada et al. 2017 (Male) | 0.63 (0.56, 0.71) | 8.00 |
| Sawada et al. 2017 (Female) | 0.81 (0.70, 0.93) | 7.44 |
| Ihira et al. 2018 (Male) | 0.85 (0.75, 0.96) | 7.89 |
| Ihira et al. 2018 (Female) | 0.89 (0.76, 1.04) | 7.08 |
| Zhao et al. 2019 (Female) | 0.59 (0.33, 1.05) | 1.61 |
| Zhao et al. 2019 (Male) | 0.41 (0.24, 0.71) | 1.79 |
| Overall (I-squared = 59.4%, p<0.001) | 0.80 (0.74, 0.87) | 100.00 |

NOTE: Weights are from random effects analysis.

Figure 1: Flow diagram of study selection.

Figure 2: Forest plot for the association between adult height and CVD mortality by considering the highest and lowest height. Horizontal lines represent 95% CIs. Diamonds represent the pooled estimates from the random-effects analysis. RR: relative risk; CI: confidence interval.
### Table 1: Forest plot for the association between adult height and CHD mortality by considering the highest and lowest height.

| Study ID                        | RR (95% CI)   | (%) Weight |
|---------------------------------|---------------|------------|
| TunstallPedoe et al. 1997 (Male)| 0.93 (0.83, 1.03) | 9.57       |
| TunstallPedoe et al. 1997 (Female)| 0.98 (0.80, 1.20) | 7.52       |
| Wannamethee et al. 1998         | 0.82 (0.60, 1.11) | 5.41       |
| Forsean et al. 2000             | 0.73 (0.56, 0.95) | 6.22       |
| Goldbourt and Tanne. 2001       | 0.97 (0.81, 1.15) | 8.14       |
| McCarron et al. 2002            | 0.64 (0.41, 0.99) | 3.56       |
| Song et al. 2003                | 0.97 (0.71, 1.31) | 5.44       |
| Silventoinen et al. 2006 (Male) | 0.80 (0.72, 0.89) | 9.61       |
| Silventoinen et al. 2006 (Female)| 0.84 (0.74, 0.95) | 9.23       |
| Song et al. 2008                | 0.80 (0.51, 1.25) | 3.48       |
| Wang et al. 2011 (Female)       | 1.01 (0.64, 1.61) | 3.34       |
| Wang et al. 2011 (Male)         | 1.01 (0.60, 1.72) | 2.77       |
| Sawada et al. 2017 (Male)       | 0.54 (0.46, 0.63) | 8.54       |
| Sawada et al. 2017 (Female)     | 0.61 (0.48, 0.78) | 6.66       |
| Ihira et al. 2018 (Male)        | 0.96 (0.74, 1.24) | 6.34       |
| Ihira et al. 2018 (Female)      | 0.76 (0.51, 1.11) | 4.18       |
| Overall (I-squared = 70.6%, p<0.001) | 0.82 (0.74, 0.90) | 100.00     |

### Figure 3: Forest plot for the association between adult height and CHD mortality by considering the highest and lowest height. Horizontal lines represent 95% CIs. Diamonds represent the pooled estimates from the random-effects analysis. RR: relative risk; CI: confidence interval.

### Table 2: Forest plot for the association between adult height and stroke mortality by considering the highest and lowest height.

| Study ID                        | RR (95% CI)   | (%) Weight |
|---------------------------------|---------------|------------|
| Wannamethee et al. 1998         | 0.54 (0.22, 1.31) | 1.03       |
| Goldbourt and Tanne. 2001       | 0.65 (0.47, 0.88) | 8.35       |
| McCarron et al. 2002            | 0.81 (0.39, 1.68) | 1.54       |
| Song et al. 2003                | 0.78 (0.62, 0.98) | 15.67      |
| Hozawa et al. 2006 (Male)       | 1.02 (0.52, 1.97) | 1.85       |
| Hozawa et al. 2006 (Female)     | 0.73 (0.33, 1.62) | 1.30       |
| Song et al. 2008                | 0.61 (0.48, 0.79) | 13.23      |
| Wang et al. 2011 (Female)       | 0.66 (0.47, 0.93) | 7.05       |
| Wang et al. 2011 (Male)         | 0.59 (0.37, 0.95) | 3.69       |
| Sawada et al. 2017 (Male)       | 0.67 (0.44, 1.00) | 4.87       |
| Sawada et al. 2017 (Female)     | 0.87 (0.51, 1.15) | 4.97       |
| Ihira et al. 2018 (Male)        | 0.78 (0.67, 0.97) | 23.99      |
| Ihira et al. 2018 (Female)      | 0.83 (0.64, 1.07) | 12.44      |
| Overall (I-squared = 0.0%, p = 0.802) | 0.73 (0.67, 0.80) | 100.00     |

### Figure 4: Forest plot for the association between adult height and stroke mortality by considering the highest and lowest height. Horizontal lines represent 95% CIs. Diamonds represent the pooled estimates from the random-effects analysis. RR: relative risk; CI: confidence interval.
exposure assessment and follow-up duration appeared to be the main sources of heterogeneity. Moreover, a significant inverse association was seen in most subgroup analyses. The sensitivity analysis showed that excluding any single study from the analysis did not appreciably alter the pooled effect sizes.

4. Discussion

The summary data from cohort studies indicated that adult height was inversely associated with the risk of cardiovascular mortality. Moreover, we found a significant inverse association between adult height and the risk of death from coronary disease and hemorrhagic stroke, while no clear association was seen with ischemic stroke mortality.

CVD is a leading cause of death and a major global health threat. Although height attainment is generally not under individual control, it is a widely available index reflecting the interaction of genetics and various early life conditions. It may indicate underlying mechanistic pathways relevant to the risk of developing CVD. The current study provides up-to-date and reliable evidence on the association between adult height and CVD mortality.
We found that adult height was inversely associated with CVD mortality. Consistent with our findings, a previously published meta-analysis reported that greater height was associated with a lower risk of all cardiovascular deaths [29]. Our results were also in line with the findings from a large-scale individual data pooling project, in which an inverse linear association was seen between height and CVD risk [9]. A potential biological pathway for this association is a positive association between height with insulin sensitivity and insulin-like growth factor 1 (IGF-1), which predicts a lower risk of CVD [30, 31].

The present study has confirmed that taller individuals have a lower risk of death from coronary disease. In a multilocus Mendelian randomization meta-analysis, taller height was associated with a lower risk of CHD, with possible explanations such as better lung function, lower levels of adiposity, lipid profiles, and blood pressure [32]. The findings of the recent individual participant meta-analysis also demonstrated that adult height was inversely associated with the risk of fatal and non-fatal CHD events [9]. A similar finding was also seen in a meta-analysis that examined the associations between BMI and height during childhood and adolescence with the risk of coronary diseases in adulthood. The investigators reported that height in youth was inversely associated with a lower risk of CHD [33]. Moreover, evidence from another meta-analysis showed that adults within the shortest category had a 50% higher risk of CHD morbidity and mortality than tall individuals [30]. Overall, together with all available studies, our findings provide further evidence of an inverse association between height and CHD mortality. This might be explained by narrow coronary arteries and faster heart rate in short individuals, conditions that are involved in the pathogenesis of arterial occlusive events [34].

In this meta-analysis, taller people had a lower risk of death from stroke, especially hemorrhagic stroke mortality. However, we failed to find an inverse association between adult height and ischemic stroke mortality. Unlike our findings, a meta-analysis of 121 prospective cohort studies showed that adult height was inversely associated with fatal and nonfatal ischemic stroke events. However, this study aligns with our findings reported an inverse relationship between height and hemorrhagic stroke events [9]. The exact explanation for conflicting evidence of the link between adult height and the risk of stroke subtypes is unclear. It is thought that shorter adult height is closely associated with poor nutrition and socio-economic conditions during childhood. It has been suggested that hemorrhagic stroke may be more affected by such conditions than ischemic stroke [35, 36]. Furthermore, the lack of a significant association between height and ischemic stroke mortality in our meta-analysis might be related to the relatively small number of included studies.

Multiple lines of evidence support mechanisms through which taller heights may decrease the risk of CVD mortality. Low socio-economic position in childhood might be considered a possible mechanism for an increased risk of CVD in later life [37, 38]. These conditions in childhood may be reflected in the physical feature of short stature and may lead to an increased future risk of mortality from CVD. Moreover, elevated concentrations of IGF-1 are associated with a lower risk of vascular disease [31, 39]. It has been shown that IGF-1 improves vascular endothelial function and myocardial apoptosis [40, 41]. Additionally, shorter adult height has been associated with increased primary systolic pulse augmentation, leading to increased central aortic pressure [42].

4.1. Strengths and Limitations. The large number of participants and deaths, prospective nature of included studies, and consideration of subtypes of CVD mortality are the major strengths of this study. Our meta-analysis also has some limitations that should be considered when interpreting the results. As a meta-analysis of cohort studies, confounding by unmeasured risk factors might have influenced our findings. We found significant heterogeneity in some analyses. The number of studies in stratified analyses was limited to fully explore between-study heterogeneity. Some included studies in the current meta-analysis used self-reported heights rather than measured ones, which might have biased our findings. However, most validation studies have found a strong correlation between self-reported and measured height; nevertheless, some over-reporting of height can occur. Although there was no evidence of publication bias in our analysis, it is still possible that some studies with null findings have remained unpublished. The data on covariates used in primary studies were assessed based on single measurement at the study baseline, and their changes throughout the follow-up were not considered in the original analyses.

5. Conclusion

In conclusion, our results indicated that greater height was associated with a lower risk of death from CVD, CHD, and stroke. Well-designed, large prospective studies are required to obtain a better indication of the relationship.

Data Availability

The datasets generated and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors declared that they have no conflicts of interest.

Authors’ Contributions

OF and ZK contributed to the literature search. OF and SN contributed to data extraction and data analysis. AE and ZK contributed to the study conception, manuscript drafting, data analysis, and approving the final manuscript. All authors acknowledge the responsibility for the analyses and interpretation of the report.
Supplementary Materials

Supplemental Table 1: medical subject headings (MeSH) and non-MeSH keywords used to search relevant publications. Supplemental Table 2: characteristics of the included studies on the association between adult height and risk of cardiovascular mortality. Supplemental Table 3: quality assessment of prospective cohort studies included in the current systematic review and meta-analysis on the association between height CVD mortality based on the Newcastle-Ottawa scale. Supplemental Table 4: stratified analysis on the association of adult height with the risk of mortality from CVD, CHD, and stroke. (Supplementary Materials)

References

[1] WHO, Cardiovascular Diseases (CVDs), World Health Organization, Geneva, Switzerland, 2021.
[2] J. Opio, E. Croker, G. S. Odongo, J. Attia, K. Wynne, and M. McEvoy, "Metabolically healthy overweight/obesity are associated with increased risk of cardiovascular disease in adults, even in the absence of metabolic risk factors: a systematic review and meta-analysis of prospective cohort studies," Obesity Reviews: An Official Journal of the International Association for the Study of Obesity, vol. 21, no. 12, Article ID e13127, 2020.
[3] K. Silventoinen, "Determinants of variation in adult body height," Journal of Biosocial Science, vol. 35, no. 2, pp. 263–285, 2003.
[4] S. Rohrmann, S. R. Haile, K. Staub, M. Bopp, and D. Faeh, "Body height and mortality—mortality follow-up of four Swiss surveys," Preventive Medicine, vol. 101, pp. 67–71, 2017.
[5] N. Sawada, P. A. Wark, M. A. Merritt et al., "The association between adult attained height and sitting height with mortality in the European prospective investigation into cancer and nutrition (EPIC)," PLoS One, vol. 12, no. 3, Article ID e0197164, 2018.
[6] Y. M. Song, G. D. Smith, and J. Sung, "Adult height and cause-specific mortality: a large prospective study of South Korean men," American Journal of Epidemiology, vol. 158, no. 5, pp. 479–485, 2003.
[7] Y. M. Song and J. Sung, "Adult height and the risk of mortality in South Korean women," American Journal of Epidemiology, vol. 168, no. 5, pp. 497–505, 2008.
[8] P. R. Hebert, J. W. Rich-Edwards, J. E. Manson et al., "Height and incidence of cardiovascular disease in male physicians," Circulation, vol. 88, no. 4, pp. 1437–1443, 1993.
[9] S. G. Wannamethee, A. G. Shaper, P. H. Whincup, and M. Walker, "Adult height, stroke, and coronary heart disease," American Journal of Epidemiology, vol. 148, no. 11, pp. 1069–1076, 1998.
[10] Emerging Risk Factors Collaboration, "Adult height and the risk of cause-specific death and vascular morbidity in 1 million people: individual participant meta-analysis," International Journal of Epidemiology, vol. 41, no. 5, pp. 1419–1433, 2012.
[11] Y. Zhao, M. Zhang, Y. Liu et al., "Adult height and risk of death from all-cause, cardiovascular, and cancer-specific disease: the rural chinese cohort study," Nutrition, Metabolism, and Cardiovascular Diseases, vol. 29, no. 12, pp. 1299–1307, 2019.
[12] H. Ihira, N. Sawada, M. Iwasaki et al., "Adult height and all-cause and cause-specific mortality in the Japan public health center-based prospective study (JPHC)," PLoS One, vol. 13, no. 5, Article ID e0197164, 2018.
[13] J. P. Higgins and S. Green, Cochrane Handbook for Systematic Reviews of Interventions, Wiley-Blackwell, Hoboken, NJ, USA, 2008.
[14] J. Hamling, P. Lee, R. Weitkunat, and M. Ambühl, "Facilitating meta-analyses by deriving relative effect and precision estimates for alternative comparisons from a set of estimates presented by exposure level or disease category," Statistics in Medicine, vol. 27, no. 7, pp. 954–970, 2008.
[15] N. R. Cook, P. R. Hebert, S. Satterfield, J. O. Taylor, J. E. Buring, and C. H. Hennekens, "Height, lung function, and mortality from cardiovascular disease among the elderly," American Journal of Epidemiology, vol. 139, no. 11, pp. 1066–1076, 1994.
[16] P. Jousilahti, J. Tuomilehto, E. Vartiainen, J. Eriksson, and P. Puska, "Relation of adult height to cause-specific and total mortality: a prospective follow-up study of 31,199 middle-aged men and women in Finland," American Journal of Epidemiology, vol. 151, no. 11, pp. 1112–1120, 2000.
[17] M. J. Gardner and D. G. Altman, "Confidence intervals rather than P values: estimation rather than hypothesis testing," British Medical Journal, vol. 292, no. 6522, pp. 746–750, 1986.
[18] W. A. van Enst, E. Ochodo, R. J. Scholten, L. Hooft, and M. M. Leeflang, "Investigation of publication bias in meta-analyses of diagnostic test accuracy: a meta-epidemiological study," BMC Medical Research Methodology, vol. 14, no. 1, p. 70, 2014.
[19] G. D. Smith, C. Hart, M. Upton et al., "Height and risk of death among men and women: aetiological implications of associations with cardiorespiratory disease and cancer mortality," Journal of Epidemiology and Community Health, vol. 54, no. 2, pp. 97–103, 2000.
[20] T. Forsén, J. Eriksson, Q. Qiao, M. Tervahauta, A. Nissinen, and J. Tuomilehto, "Short stature and coronary heart disease: a 35-year follow-up of the finnish cohorts of the seven countries study," Journal of Internal Medicine, vol. 248, no. 4, pp. 326–332, 2000.
[21] U. Goldbourt and D. Tanne, "Body height is associated with decreased long-term stroke but not coronary heart disease mortality?" Stroke, vol. 33, no. 3, pp. 743–748, 2002.
[22] A. Hozawa, Y. Murakami, T. Okamura et al., "Relation of adult height with stroke mortality in Japan: NIPPON DATA80," Stroke, vol. 38, no. 1, pp. 22–26, 2007.
[23] J. P. Kannm, D. Levy, M. Larson, and P. W. Wilson, "Short stature and risk for mortality and cardiovascular disease events. The framingham heart study," Circulation, vol. 90, no. 5, pp. 2241–2247, 1994.
[24] P. McCarron, M. Okasha, J. McEwen, and G. D. Smith, "Height in young adulthood and risk of death from cardiorespiratory disease: a prospective study of male former students of glasgow University, Scotland," American Journal of Epidemiology, vol. 155, no. 8, pp. 683–687, 2002.
[25] K. Silventoinen, S. Zdravkovic, A. Skytte et al., "Association between height and coronary heart disease mortality: a prospective study of 35,000 twin pairs," American Journal of Epidemiology, vol. 163, no. 7, pp. 615–621, 2006.
[26] H. Tunstall-Pedoe, M. Woodward, R. Tavendale, R. A. Brook, and M. K. McCluskey, "Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish heart health study: cohort study," BMJ, vol. 315, no. 7110, pp. 722–729, 1997.
[27] N. Wang, X. Zhang, Y. B. Xiang et al., "Associations of adult height and its components with mortality: a report from
cohort studies of 135,000 Chinese women and men,” *International Journal of Epidemiology*, vol. 40, no. 6, pp. 1715–1726, 2011.

[28] A. V. Margulis, M. Pladevall, N. Riera-Guardia et al., “Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the newcastle-ottawa scale and the RTI item bank,” *Clinical Epidemiology*, vol. 6, pp. 359–368, 2014.

[29] T. A. Paajanen, N. K. Oksala, P. Kuukasjärvi, and P. J. Karhunen, “Short stature is associated with coronary heart disease: a systematic review of the literature and a meta-analysis,” *European Heart Journal*, vol. 31, no. 14, pp. 1802–1809, 2010.

[30] J. A. M. J. L. Janssen, R. P. Stolk, H. A. P. Pols, D. E. Grobbee, and S. W. J. Lamberts, “Serum total IGF-I, free IGF-I, and IGFB-1 levels in an elderly population: relation to cardiovascular risk factors and disease,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 18, no. 2, pp. 277–282, 1998.

[31] H. Iso, K. Maruyama, S. Ikemura, K. Yamagishi, and A. Tamakoshi, “Cellular growth factors in relation to mortality from cardiovascular disease in middle-aged Japanese: the JACC study,” *Atherosclerosis*, vol. 224, no. 1, pp. 154–160, 2012.

[32] E. Nüesch, C. Dale, T. M. Palmer et al., “Adult height, coronary heart disease and stroke: a multi-locus Mendelian randomization meta-analysis,” *International Journal of Epidemiology*, vol. 45, no. 6, pp. 1927–1937, 2016.

[33] J. F. Meyer, S. B. Larsen, K. Blond, C. T. Damsgaard, L. G. Bjerregaard, and J. L. Baker, “Associations between body mass index and height during childhood and adolescence and the risk of coronary heart disease in adulthood: a systematic review and meta-analysis,” *Obesity Reviews: An Official Journal of the International Association for the Study of Obesity*, vol. 22, no. 9, Article ID e13276, 2021.

[34] C. P. Nelson, S. E. Hamby, D. Saleheen et al., “Genetically determined height and coronary artery disease,” *New England Journal of Medicine*, vol. 372, no. 17, pp. 1608–1618, 2015.

[35] B. Galobardes, J. W. Lynch, and G. Davey Smith, “Childhood socioeconomic circumstances and cause-specific mortality in adulthood: systematic review and interpretation,” *Epidemiologic Reviews*, vol. 26, no. 1, pp. 7–21, 2004.

[36] B. Galobardes, J. W. Lynch, and G. D. Smith, “Is the association between childhood socioeconomic circumstances and cause-specific mortality established? update of a systematic review,” *Journal of Epidemiology and Community Health*, vol. 62, no. 5, pp. 387–390, 2008.

[37] B. Galobardes, G. D. Smith, and J. W. Lynch, “Systematic review of the influence of childhood socioeconomic circumstances on risk for cardiovascular disease in adulthood,” *Annals of Epidemiology*, vol. 16, no. 2, pp. 91–104, 2006.

[38] D. Blane, C. L. Hart, G. D. Smith, C. R. Gillis, D. J. Hole, and V. M. Hawthorne, “Association of cardiovascular disease risk factors with socioeconomic position during childhood and during adulthood,” *BMJ*, vol. 313, no. 7070, pp. 1434–1438, 1996.

[39] A. Juul, T. Scheike, M. Davidsen, J. Gyllenborg, and T. Jørgensen, “Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study,” *Circulation*, vol. 106, no. 8, pp. 939–944, 2002.

[40] W. L. Lee, I. W. Chen, C. T. Ting et al., “Insulin-like growth factor I improves cardiovascular function and suppresses apoptosis of cardiomyocytes in dilated Cardiomyopathy1,” *Endocrinology*, vol. 140, no. 10, pp. 4831–4840, 1999.